08:19 AM EDT, 03/24/2025 (MT Newswires) -- Genmab ( GMAB ) denied Saturday allegations of misappropriating trade secrets related to the use of disaccharides in antibody-drug conjugates in a lawsuit filed by AbbVie (ABBV).

The company said it would defend itself against AbbVie's ( ABBV ) complaint, which also named ProfoundBio and former AbbVie employees as defendants. Genmab ( GMAB ) acquired ProfoundBio in May 2024.

AbbVie is seeking damages and injunctions but is not pursuing patent enforcement, Genmab ( GMAB ) said.

Genmab ( GMAB ) said its collaboration with AbbVie on the epcoritamab program will not be affected by the lawsuit.

AbbVie did not immediately respond to MT Newswires' request for comment.